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Abstract 
Organic synthesis has many applications in the chemical field. A frequent reaction used in 
organic synthesis is amide bond formation. Amide bond formation is commonly achieved through 
the combination of an amine and an activated carboxylic acid. Amide bonds link together amino 
acids to form peptides in biological systems. Reports of amide bond formation through the direct 
coupling of carboxylic acids and amines are non-existent as the favored reaction between the amine 
and carboxylic acid is an equilibrium reaction. The forward reaction, bond formation, products 
water and is a condensation reaction. The reverse reaction is a hydrolysis reaction where water can 
hydrolyze the newly formed bond. Recently, we have developed a method for the direct coupling 
of the amine and carboxylic acid using nano-reactors. The nano-reactors have four characteristics 
that allows them to facilitate direct amide bond coupling: (1) Nano-reactors absorb organic 
molecules into central cavities. (2) Upon absorption of organic molecules, the nano-reactor swells 
3-5 times its dry volume (3) The nano-reactor is hydrophobic, water does not enter the central 
cavity and water synthesized in the cavity migrates out of the cavity. The produced water is 
expelled from the hydrophobic nano-reactor driving the reaction forward. When applied to the 
synthesis of proteins, which has challenged chemists for over a century, trial syntheses conducted 
using nano-reactors and amino acids occur with high efficiency and yield. These advancements 
can be applied to peptide synthesis for the use of vaccines. The authors will present an optimized 
procedure for the direct coupling of amino acids and its subsequent use in the synthesis of several 
di-peptides.   
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Chapter 1: Applications to Biology 
Vaccines were first documented and administered by Edward Jenner in 1776. Since then 
the methods for creating vaccines that are not only more effective and safe for the public has been 
on the scientific radar. One of the new advances and considerations for vaccines is the introduction 
of peptide vaccines. The majority of vaccines on the market today contain killed whole pathogens, 
viruses, and or purified proteins produced from bacteria in the lab. Some of the major concerns for 
traditional vaccines are the yield of purified proteins and the strong allergic responses for patients 
who receive these types of vaccines. The whole pathogens usually elicit longer lasting immunity, 
however they also can cause strong allergic or autoimmune responses in the patient (Skwarczynski 
et. al. 2016). Peptide-based vaccines have some advantages over whole pathogen vaccines. 
Peptide-based vaccines are more customizable and can be engineered to target several strains or 
different life stages of pathogens (Skwarczynski et. al. 2016). Peptide based antigens are also less 
likely to induce allergic reactions or autoimmune responses due to a lack of redundant elements 
(Skwarczynski et. al. 2016). Both biological and synthetic systems can be used to synthesize 
peptides and proteins. 
Peptide/Protein Synthesis with Escherichia coli 
Peptides, and whole proteins, can be produced and purified from Escherichia coli cultures. 
For this method plasmids are chosen to transform into the E. coli cultures that will then start 
synthesizing the peptide of interest. Culturing E. coli for this process is convenient due to extensive 
research and data collected on E. coli as a model organism. E. coli is also relatively easy to culture 
in the lab and cultures can achieve a high cell density quickly on readily available media. These 
aspects of E. coli allow for this method to be very cost effective and allow for a high protein 
purification yield due to the sheer number of cells in culture (Rosano 2014). In practice there are 
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many factors to consider when synthesizing proteins in E. coli. Before transforming a plasmid into 
the culture, an appropriate plasmid must be designed to express the peptide or protein of interest 
at the most effective yield. The replicon of the plasmid should contain an appropriate origin of 
replication region, promoter, the coding sequence, any affinity tags, sequence for tag removal, a 
terminator sequence, and a selection marker.  
Through PCR and reverse transcription methods, mRNA from human or microbial cells 
can be reverse transcribed into a cDNA that is ready for insertion into a desired plasmid. The 
resulting cDNA’s contain no introns and can be used as templates for protein/peptide expression 
in prokaryotic organisms. This allows for proteins/peptides to be expressed that do not need to be 
spliced, taking away one of the modifications needed. Restriction enzymes produce 
complementary sticky ends that can be ligated with ligase to produce a recombinant plasmid. This 
recombinant plasmid of interest should contain the cDNA insert and the plasmid vector chosen to 
insert into the E. coli. Plasmids up to 10,000 base pairs have been shown to be successfully 
transformed into E. coil without loss of transformation frequency (Inoue 1990). 
Transformation of the plasmid into E. coli cultures has been optimized by Inoue et. al for 
the overall process. Certain strains of E. coli were presented as competent cells that are optimal 
for transformation including strains DH5α, JM109, HB101 (Inoue 1990). To make cells competent 
for transformation the cells are usually treated with a salt, like calcium chloride (CaCl2) to prep 
the cells for transformation of the plasmid. The full role of CaCl2 is not entirely understood, 
however CaCl2 is thought to open pores in the membrane of the cells and provide a positive counter 
charge allowing for the intake of negatively charged plasmid DNA. Salts that can be removed from 
the E. coli include KCl, CaCl2, MnCl2, and K ∙ acetate. Other salts are shown to be inhibitory for 
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transformation (Inoue 1990). A heat shock can be used to promote the plasmid DNA being taken 
up by the E. coli after the cells have been prepped with salts. 
The first concern and method of controlling the amount of protein synthesized in the E. 
coli culture is the origin of replication in the recombinant plasmid. Origin regions control the copy 
number of the plasmid being synthesized which will affect the amount of protein/peptide 
synthesized. For example, ori pSC101 will make less than 5 copies of the plasmid while ori pUC 
will make 500-700 copies of the plasmid per cell in the culture (Rosano 2014). This is important 
for keeping the E.coli culture healthy and producing peptides for a longer period. Some proteins 
at higher concentrations can cause cell lysis or will elicit the protein degradation system in the cell 
(Rosano 2014). Both processes result in loss of the protein yield. Cell lysis will affect the 
surrounding cells as well by releasing proteases into the culture that could potentially cause a 
complete loss of the culture and synthesized protein. Besides preventing loss of peptide or protein 
yield, higher concentrations of the protein in solution will hinder correct folding of the 
protein/peptide or cause aggregation. The shape of a protein is a large factor in that proteins 
function. If a larger amount of protein is produced but is folded incorrectly, it will be ineffective 
in a vaccine. Protein aggregated out of solution will also be ineffective for vaccine use. 
Promoters also play a large role in the expression level of proteins and the most commonly 
used is the lac promoter. This promoter, having been studied thoroughly, is under positive control 
due to catabolite repression. Lactose can be used to induct of the system resulting in protein 
production (Rosano 2014). This allows for control over the promoter but the yield level for the lac 
promoter is weak, therefore synthetic promotors are available that can combine the control of the 
lac promoter with the strength of another promoter (Rosano 2014). The default promoter is usually 
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the T7 system that allows for control over the system and allows for the protein/peptide of interest 
to consist of up to 50% of the total protein yield of the cell (Rosano 2014). 
Plasmids should also include selection markers for distinguishing between bacteria 
successfully transformed with the plasmid and bacteria without the presence of a plasmid. To do 
this an antibiotic resistant gene is placed into the plasmid backbone. When bacteria are successfully 
transformed with the plasmid, those cells can grow on media containing that antibiotic. This is 
useful in collecting the transformed colonies; however, antibiotics are costly and getting rid of any 
resistance before the protein/peptide is inserted into the vaccine is a major concern (Rosano 2014). 
Some plasmid systems have been developed that are antibiotic free and use plasmid addiction to 
select for transformed cells. Plasmid addiction occurs when cells without the plasmid are unable 
to grow. This involves the deletion of an essential gene in the E. coli’s genome and then 
introducing that gene back into the cell with the plasmid (Rosano 2014). 
Affinity tags and their removal are also a concern for synthesizing proteins/peptides from 
E. coli. Affinity tags allow for the removal or purification of the protein/peptide out of the cells 
once the production process is over. Affinity tags can be utilized in western blots, antibody stain, 
and column chromatography. These tags should be relatively small as to not interfere with the 
tertiary folding of the protein of interest (Rosano 2014). Tags can be removed by chemical or 
enzymatic cleavage (Rosano 2014). Chemical cleavage allows for easy elimination, but the 
reaction conditions are harsh, limiting the number of proteins that can use this system and this 
cleavage can also result in unwanted protein modification (Rosano 2014).  Removal of the affinity 
tag is a concern because the solubility of the desired protein/peptide is unpredictable (Rosano 
2014). This varies from protein to protein and calls for multiple rounds of protein synthesis and 
purification.  
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Peptide/Protein Synthesis with Baculovirus Vectors 
 Baculoviruses are a part of the family Baculoviridae that infects invertebrate cells and have 
been used to infect mammalian cells in the lab. Baculoviruses can infect mammalian cells in the 
lab but are unable to reproduce in mammalian or vertebrate cells. Proteins/peptides can also be 
synthesized and purified using a baculovirus vector system. In this system the sequence for the 
gene is incorporated into in the baculovirus genome (Kost 2005). This vector allows for expression 
in insect and mammalian cells rather than bacteria culture like E. coli.  Infection of insect cells will 
allow for 3 to 5 days of synthesis before cell lysis occurs (Kost 2005). Lysis of this system, like 
the lysis of the E. coli cells, results in the release of proteases that can chew up protein/peptide 
product before collection of the product. To avoid time limits on protein production, strains of the 
baculovirus have been engineered with a reduced capability for cell lysis (Kost 2005). These 
modified strains show an average of 53% less cell lysis after the 5 day mark compared to the parent 
virus (Kost 2005).   
  Expression in eukaryotic cells, usually in insect systems, can help to ensure that the 
protein/peptide product will be folded, modified, and trafficked correctly (Kost 2005). Co-
expression of chaperone proteins with the protein of interest in this system aids in the correct 
folding of the protein/peptide (Kost 2005). This feature of the baculovirus system is an advantage 
over the E. coli system. Expression of proteins/peptides in E. coli would not have eukaryotic 
modifications. Examples of eukaryotic modifications include but are not limited to 
phosphorylation and glycosylation. This system is useful for proteins that require a large amount 
of specific folding and if several subunits are needed to form the active product. All of the subunits 
can be encoded for and expressed at the same time. Multiple cultures of baculaviruses can be 
generated so that each culture expressed a single protein at a specific concentration. Co-infection 
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of cells from the different cultures then allows for control over the expression of multiple 
proteins/peptides each at specific concentrations. This fine-tuning aspect of this system allows for 
a more flexible approach for expression of multiple proteins/peptides at the same time. Also, if co-
expression of many extra proteins is necessary then co-infection can ensure that a single culture is 
not overloaded.  
As mentioned the baculovirus can be used to make virus like particles (VLPs) which cannot 
replicate in mammalian cells but can induce an immune response by presenting antigens to the 
immune system (Kost 2005). This expression system is used to produce VLPs for the current 
vaccine Cervarix® to prevent infection by the human papillomavirus (Senger et. al. 2009). Of the 
200 types of human papillomavirus (HPV) there are two main groups, cutaneous and mucosal, 
based on what is being infected (Senger et. al. 2009). Cutaneous HPV infects the skin causing skin 
warts or epithelial tumors; mucosal HPV causing genital warts and anogenital cancer (Senger et. 
al. 2009). Cervarix® prevents HPV types 16 and 18 which cause 70% of cervical cancer cases 
(Senger et. al. 2009). Very low yields of protein expression for certain types of HPV were a 
concern for the baculovirus expression system. Now with improved methods of expression, 
MultiBac system, these proteins can be increased and controlled by the polyhedron (polh) or the 
p10 promotor (Senger et. al. 2009).  Large amounts of the proteins for different types of HPV are 
able to be produced using the optimizations presented by Senger et. al, however, the team did not 
research the genetic stability of the MultiBac baculoviruses (Senger et. al. 2009). Genetic stability 
and ensuring gene preservation is an important concern for large scale vaccine productions.  For 
this optimized system to be considered for vaccine productions further studies must be made on 
the genetic stability. 
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  Furthermore, baculoviruses can be used for gene delivery in mammalian cells by carrying 
mammalian cell- active expression cassettes; these viruses are referred to as BacMan viruses (Kost 
2005). Many different cells types can receive genes from the BacMan virus making it an ideal 
system for gene therapy and targeted peptide delivery. The BacMan virus also cannot replicate in 
mammalian cells and is therefore unable to generate a new viral infection (Kost 2005). Studies 
using the BacMan method have reported significant toxicity in response to possible induction of 
inflammatory cytokines in response to viral delivery (Kost 2005). Creating strains that are less 
prone to complication of this kind are in the works (Kost 2005). 
Peptide/Protein Synthesis with Transient Expression Systems 
Transient expression systems first introduce the gene and then begin harvesting protein 
similar to other systems. The gene of interest is not incorporated into the host genome and may 
need to be reintroduced to the system multiple times. This system might be used in instances where 
the protein of interest may need to be expressed at precise levels to avoid toxicity. Generally, this 
system shows lower aggregation and lysis rates and thus fewer problems with producing “too much 
protein”. Furthermore, this expression system, like the E. coli, system does use affinity tags and 
columns for protein harvesting. The use of columns is common and affinity tags can be inserted 
into the DNA without too much complication. Though not specified in Wurm et. al, similar 
concerns for affinity tag removal would most likely be present for this system like the concerns of 
tag removal in the E. coli expression system. 
The methods for transient expression can be divided into two categories: viral vector and 
plasmid vector systems. Both systems have some advantages to them. These methods are relativity 
simple in terms of processes and techniques used. Production of protein occurs in a few days in a 
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wide range of host cell lines. Due to the shorter production time, shorter time between generation 
of vector and the product recovery, there is more genetic stability and consistency (Wurm 1999). 
Expression in mammalian cells can be achieved by transient expression in viral vectors 
such as the adenovirus and vaccinia vectors. The adenovirus transcription virus has been studied 
thoroughly over the years allowing for the creation of heterologous expression systems (Wurm 
1999). In these systems, early regions of the genome have been deleted to prevent viral replication. 
Replication is restored in trans by the host cell and the gene of interest is placed under control of 
a late promoter, allowing for expression after other viral machinery (Wurm 1999). This viral vector 
system is able to be increased to large scale production by propagation in suspension cell cultures. 
Vaccinia vectors are ideal for large scale infection in rates of 5000 virus particles per cell (Wurm 
1999).  This vector system is also placed under control of a late promoter. In both cases, late 
promoters are ideal for high levels of protein/peptide expression and earlier promoters can be 
chosen to decrease the level of protein expression. Vaccinia vectors can also target a large variety 
of hosts (Wurm 1999). A draw back to these systems include a high safety level for labs which 
may require more money and equipment driving up the cost of the protein/peptide product for 
vaccines. 
Transient expression is also possible in plasmid vector systems. DNA delivery methods for 
mammalian cells using plasmid vectors are fairly cost effective and can be utilized for adherent or 
suspended cells. Cells in suspension with plasmid vectors have been able to reach protein 
production levels of 0.1-1 pg/cell/day and are ideal for production levels up to 10 L (Wurm 1999). 
After transfection cells can remain in a producing stage at a limited time span, 5- 10 days. This 
process is not suitable for scales beyond 10 L and would not be able to be used for large scale 
protein/peptide production for mass vaccines (Wurm 1999). Transfection levels have an average 
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rate of 70% which is reliable for protein product set ups. The problems with this system lie mainly 
in the vehicle systems used. Different vehicle systems include calcium-phosphate, 
polyethylenimine (PEI), and electroporation which have all been shown to be successful vehicles 
for the larger scale transient gene expression (Wurm 1999). Both calcium-phosphate and PEI 
methods rely on endocytosis to enter the cell. There is the assumption that large amounts of DNA 
are degraded before they make it to the cell (Wurm 1999). Electroporation allows for the pores of 
the cells to open due to an electrical shock. This vehicle method can cause a large portion of cells 
to die from electric discharge, sometimes resulting in the death of 50% or the cells being 
transformed (Wurm 1999).   
A disadvantage of the transient expression system in cultivated mammalian cells at a large 
scale is that it is usually done in the presence of serum (Derouazi et. al.2004). Contamination of 
serum in a vaccine could lead to higher health risks. Also working in the presence of serum would 
require that an extra purification step must be taken to remove the serum from the synthesized 
protein. Extra steps raise the cost level of vaccine production. New experiments are being 
conducted with Chinese hamster ovary cells (CHO) and transient expression systems in a serum 
free environment. The CHO cells were transformed with green fluorescing protein (GFP) and the 
amount of fluorescence reached a maximum of 10 mg/L after 5 days’ time (Derouazi et. al. 2004). 
Derouazi et. al’s study shows that mammalian CHO cells can be cultured in the absence of serum 
and can be used to transiently express proteins.  
Peptide/Protein Synthesis with Fully Synthetic Methods 
Instead of utilizing a biological system to produce peptides/proteins, a fully synthetic 
approach can be used. The synthesis of a fully synthetic peptide is exclusively chemical which 
eliminates contamination of antigens from a biological system (Skwarczynski 2016). This leads to 
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the production of a much safer vaccine with lower risks of a severe allergic reaction. Furthermore, 
automated steps can be introduced with the use of a fully synthetic approach and can therefore 
cause the vaccine to be much more cost effective (Skwarczynski 2016). Finally, fully synthetic 
peptides can be stored under simple storage conditions, due to their water-solubility, and can be 
freeze dried (Skwarczynski 2016). 
 Solid phase synthesis is the current fully synthetic method of choice for synthesizing 
peptides. Developed by Professor Merrifield from The Rockefeller University in New York, this 
method won the Noble Prize in Chemistry in 1984. This method involves sequentially bonding 
individual amino acids, one monomer at a time. The first amino acid is covalently bound to the to 
the support material (Merrifield 1985).  Once this first amino acid is anchored, the next amino 
acids can be subsequently added. The C terminus end of the anchored amino acid is deprotected 
and the next amino acid is added (Merrifield 1985). This process continues until the last amino 
acid in the peptide is added. After the complete peptide is synthesized, the covalent bond holding 
the initial amino acid to the support system is selectively cleaved (Merrifield 1985). This same 
general process can be applied for the synthesis of polynucleotides and polysaccharides. 
 The solid support system used are cylindrical beads consisting of co-polymerized styrene 
and 1% divinylbenzene (Merrifield 801).  With the addition of organic solvents, the beads are able 
to swell up to 25-fold the size of the original dry bead which allows for solvents to penetrate to the 
interior of the bead (Merrifield 1985). The addition reactions are able to take place both on the 
surface of the bead and on the beads interior (Merrifield 1985). The combination of bead swelling 
and saturation of solvents in the beads allows for the reaction to proceed quickly (Merrifield 1985). 
Another advantage to peptide synthesis with this method is that solvation is increased, and peptides 
are less likely to aggregate. This occurs due to a mutual solvating effect that the bead and the cross-
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linked polymer chain have on each other; thermodynamically making self-aggerates less favorable 
(Merrifield 1985).  
New developments in nan-reactor technology has been made that could improve upon or 
become its own synthesis system. Nano-reactors will be explored more after a look a chemical 
reaction. 
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Chapter 2: Introduction to a Chemical Problem 
Traditional Methods of Conducting Synthesis Reactions  
A basic chemical synthesis reaction involves two molecules colliding with one another to 
form a new bond and subsequent new compound (Brown 2014). However, there are many 
variables that require optimization for a reaction to occur. These variables can be molecular: the 
number of bonds on each atom, any charges, steric hindrance, and the reactivity of the molecule’s 
side chains. They can be chemical: does the reaction require heat or light? Does the reaction need 
help from a base or an acid?  And they can be situational: how physically close are the molecules 
and how big is the reaction flask?  
Traditionally there are methods that can be used to get a reaction to proceed. These methods 
can be physical (placing the reactants in a flask with a solvent and adding a stir bar) or chemical 
(affording energy with heat/light or the addition of an appropriate acid or base).  
The Theory of Chemical Reactivity 
Collision theory and transition state theory suggest that in order for a reaction to occur 
reactants must collide in the correct orientation and possess enough energy (activation energy) 
(Brown 2014). Collisions are less likely to occur when the reacting molecules are very far apart. 
This is the case for molecules in a traditional sized flask. The molecules will spend more time 
traveling within the flask without colliding with another reactant molecule. The molecules that do 
collide but are not correctly aligned will not form product and will bounce off each other (Brown 
2014). The molecules that collide in correct alignment still require enough energy in the collision 
to break and form bonds.  
Traditionally, scientists have been able to increase the probability of reactants colliding in 
the correct orientation and with enough energy by increasing the energy, temperature, of the 
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solution and/or increasing the concentration of the reactants in the reaction and/or increasing the 
reaction time. And while these methods are successful in increasing the likelihood of collisions, 
these methods (even when optimized) often fail to produce the desired product in quantitative 
yields efficiently (Kalinski et. al. 2010).   
Problems with Traditional Reactions: Reaction Rate 
How fast reactions proceed is very important to drug and vaccine manufacturing industries. 
The time it takes to conduct a reaction factors very heavily into the cost of these medications. 
Factors that impact the rate of a reaction are the physical state of the reactants, the concentrations 
of the reactants, the temperature of the reaction, and the use of a catalysts (Brown 2014). 
Reaction rates are dependent on the physical state of the reactants.  Reactants can be in 
solid, liquid, or gas form if the two reactants are in the same state the mixture is homogenous if 
the two reactants are in different states then the mixture is considered heterogenous (Brown 2014). 
Heterogenous mixtures can be limited by the amount of contact area available between the two 
reactants. For instance, if one of the reactants (A) is in a solid state and the other reactant (B) is in 
a liquid state there is an unequal distribution of reactant A to reactant B (Brown 2014). Reactant 
A could be stirred to increase the amount of contact with reactant B, but this can take a long time 
especially if reactant A is a compact solid rather than a powder. 
Reaction rates are also dependent on the concentration of reactants. The rate can be 
increased with an increase in reactant concentration (Brown 2014). Increased concentration 
increases the probability that the two reactants will collide and increases the frequency of these 
molecular collisions, thus increasing the overall reaction rate.  
Reaction rates are also dependent on the reaction temperature.  In general, reaction rates 
increase if the temperature of the reaction is increased (Brown 2014). Typically, as a rule of thumb, 
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the reaction rate is doubled with every ten degrees increase in Celsius (Brown 2014). Increasing 
the temperature increases the energy of the reactants which increases molecular movement (Brown 
2014). If the molecules in solution are moving at a higher rate, then there is a higher probability 
more molecules will collide at velocities with sufficient energy therefore increasing the reaction 
rate. 
Reaction rates can be impacted by the presence of a catalyst. Catalysts are found in many 
cells and they are crucial for increasing biological reaction rates. Catalysts are not used up in a 
reaction, so they can be recycled and participate in many rounds of the reaction (Eisemann et. al. 
2014). Catalysts effect the collisions of molecules by binding to one or more of the reactants and 
bringing them closer together in the correct orientation. This has a profound effect and can increase 
the rate of the reaction. The use of catalysts are limited as catalysts are reaction specific, they bind 
select molecules, they require specific temperatures and pH conditions in order to work, and their 
use are often cost prohibitive (Eisemann et. al. 2014). 
Problems with Traditional Reactions: Reaction Yield 
Reaction yield is another concern for chemical reactions both in the laboratory and in an 
industrial setting. Non-quantitative yields are a driving factor in the cost of drug and vaccine 
synthesis and can be a frustrating and costly component of laboratory research. A single reaction 
that yields the desired product in 80% yield, accepted as a great yield, represents a 20% loss of 
product.  Furthermore, this becomes a huge deal for a drug synthesis that requires multiple steps. 
With each step there is a loss in yield and a loss in money. For instance, a three-step synthesis with 
a 20% loss in product in each round means that only 40% of the final product is made. If there is 
a purification step after the three-step synthesis, there is also no guarantee that you will be able to 
perfectly purify the product and get the entire 40%. After this you are looking at a lower yield of 
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20-30% of actual product you can use. At lower yields synthesis reactions like these are not 
feasible for industry level synthesis (Kalinski et. al. 2010). This monetary loss falls on the 
shoulders of the consumers of the medications who pay an inflated cost for the medication. 
Problems with Traditional Reactions: Limited Scope and Applications 
There exist sub-classes of reactions wherein reaction yields are incredibly low (<10%) or 
reactions do not progress – reactions in chemical equilibrium (Brown 2014). In these reactions, 
letting the reaction proceed for an extended period and/or under concentrated conditions should 
allow for more collisions which should then allow for more product formation, but often do not, 
which poses enormous problems for reactivity and yield. Chemical equilibrium occurs when 
opposing reactions are occurring in at the same rate so that there is a net change of zero in the 
concentration of both the reactants and products (Brown 2014). Not all chemical reactions can 
proceed in the forward and reverse directions, however, many drug synthesis reactions have at 
least one step that face equilibrium challenges (Brown 2014).  
Equilibrium reactions are governed by Le Chatelier’s Principle which states “If a system 
at equilibrium is disturbed by a change in temperature, pressure, or a component of concentration, 
the system will shift its equilibrium position so as to counteract the effect of the disturbance” 
(Brown 2014).  Removing products from the equilibrium reaction drives the reaction towards 
production formation. Reactions that exist in equilibrium are hard to complete on a benchtop scale 
(Brown 2014). It is reasonable to suggest that scaling the reaction up to a large industrial scale 
would be even more difficult. Synthesis reactions on an industrial scale depend on increasing 
temperature and pressure to drive the reaction forward. This is a harder and more costly method. 
With the removal of product, the reaction is driven forward without adding external factors and in 
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theory could allow the reaction to proceed to a 100% yield. With constant removal of product, the 
reactants will keep forming product until all of reactants are converted into product. 
O
OH
A
+ NH2 A
A
O
NH A
+ OH2
Coupling Reagents
Base,
Solvent
 
Figure 2.1. Reaction scheme for a generic direct amide bond formation 
reaction. 
 
Direct amide bond formation is a reaction that exists at equilibrium in solution. Figure 2.1 
shows the general reaction scheme. This reaction is a condensation reaction and forms water as 
one of the products in the forward reaction. Water that is produced can hydrolyze the newly formed 
amide bond in the reverse reaction. Yields for this type of reaction in solution are extremely low 
(Brown 2014). Through traditional reaction methods, it is hard to remove water from the reaction. 
Industries and laboratories choose to increase the temperature to drive the reaction towards product 
formation (Kalinski 2014).  
SOMS as Nano-Reactor for Synthesis – A New Way to Run Reactions 
Swellable organically modified silica (SOMS), commercially known as Osorb®, is 
traditionally used for decontaminating water (Edminston 2009).  As the name implies, SOMS’ 
structure is a form of modified silica that takes the form of a hollow sphere. SOMS is porous and 
allows for molecules from the external environment to enter the central cavity. The porous nature 
of SOMS attributes to the swellable portion of the name. As molecules enter the central cavity, 
SOMS will expand, or swell, to accommodate the molecules (Edmiston et. al. 2009). SOMS can 
be manufactured to swell to different sizes. For example, some SOMS in the lab can swell to 3 
times its original size (Edminston et. al 2011). The organic modifications of SOMS gives it a 
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hydrophobic nature that repels water from entering and drives it out of the central cavity if it is a 
side product (Edminston et. al.2009). 
SOMS can be used as a nano-reactor because SOMS absorbs organic molecules into a 
central cavity (Shaw 2017). These molecules are free to react within the central cavity and then 
can be washed out with excess solvent. Secondly, SOMS swells to 3-5 times its original size when 
the organic molecule is adsorbed and absorbed (Shaw 2017). This characteristic allows SOMS to 
accommodate many molecules at once. Thirdly, selective removal of organic material from a 
multi-component mixture of organic material collapses the SOMS, concentrating the remaining 
organic material - upon complete removal of organic molecules, SOMS resumes its original size 
(Shaw 2017). which allows for SOMS to be reused. Lastly, SOMS is hydrophobic. Water cannot 
enter the central cavity and any water that is produced during the reaction migrates out of the center 
cavity (Shaw 2017). SOMS can be used to simplify traditional reactions through its nano-reactor 
characteristics. 
Problems Solved with SOMS Nano-Reactors: Reaction Rate 
SOMS aids in the collisions between the reactants thus effectively reducing reaction time. 
Adsorption and subsequent absorption of organic solvent and reactants causes the SOMS to swell 
and accommodate the molecules (Shaw 2017). Selective removal of solvent molecules collapses 
the SOMS forcing the reactants into a confined space and where they have less room to move 
around (Shaw 2017). This process is referred to as a flex or a single closing of SOMS. The confined 
space increases the probability of collisions between molecules effectively increasing the rate of 
the reaction.  
As described, SOMS can swell to accommodate solvent and reactant molecules to enter 
the central cavity (Edminston et. al. 2009). Solvent is then selectively removed to condense the 
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SOMS, bringing the molecules in close proximity to one another. Solvent can be reintroduced to 
the SOMS to make it swell again and the solvent can be selectively removed again. This swelling 
and contracting called a ‘flex’ (Shaw 2017). The solvent removal process is both efficient and 
relatively fast. This allows a flex to be quick. Figure 2.2 shows percent conversion, with and 
without the use of SOMS, of canola oil into biodiesel compared to the number of closes (Shaw 
2017). Figure 2.2 shows that 96% conversion is achieved after three flexing steps. A lower number 
of flex steps combined with the speed of each step effectively reduces the overall reaction time. 
 
 
Figure 2.2. Comparison between a traditionally conducted 
imine condensation reaction (orange) and the same imine 
condensation reaction conducted in SOMS nano-reactors (blue).   
A system can be devised to allow the reaction vessel to flex multiple times over the course 
of an hour (Shaw 2017). This flexing station takes advantage of reflux to selectively remove the 
solvent, close the SOMS, and then condense the solvent to return and allow the SOMS to swell 
again (Shaw 2017). Flexing strength can be increased if a more powerful system is used to 
selectively remove solvent (Shaw 2017). This is the case for flexes that occur on the rotary 
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evaporator. More of the solvent is removed and the SOMS closes completely. This increases the 
percent conversion per flex. 
Problems Solved with SOMS Nano-Reactors: Reaction Yield 
SOMS increases reaction yield. The confined space of the central cavity in SOMS can 
increase yield since the number of molecular collisions has increased.  Figure 2.3 demonstrates 
the increased reactivity with conversion of canola oil into biodiesel (Shaw 2017). Each close, or 
flex, of the SOMS increases the percent conversion. 
 
 
Figure 2.3. Dependence of reaction progress on the number of closes for the 
conversion of canola oil into biodiesel fuel.  
  In SOMS the molecules no longer have to travel great distances to find each other, as in a 
traditional reaction flask. More flexes provide multiple opportunities for the reactant molecules to 
collide and form product. After each sequential closing or flexing of SOMS, more product is 
formed (Shaw 2017). 
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Problems Solved with SOMS Nano-Reactors: Expanding Scope and Limitations 
  Amide bonds link amino acids in proteins and are referred to as peptide bonds. Peptide 
bond formation occurs when the carboxyl end of one amino acid interacts with the amino end of 
another amino acid. This reaction follows the general direct amidation scheme presented in Figure 
2.1. As demonstrated in Figure 2.1, water is a product of peptide bond formation and is a 
condensation reaction. Water molecules can also cleave peptide bonds through hydrolysis. SOMS 
can be used to solve problems with the direct amidation or peptide bond formation in solution by 
preventing water from being initially present in the reaction and by driving out water produced 
from bond formation (Edminston et. al. 2009). 
SOMS has a hydrophobic nature and will prevent any water from entering the central cavity 
(Shaw 2017). This prevents water from being present to immediately hydrolyze a newly formed 
peptide bond. As water is produced from peptide bond formation, the hydrophobic nature of SOMS 
will also drive it out of the reaction cavity (Shaw 2017). This prevents water from running the 
reverse hydrolysis reaction. Using Le Chatelier’s principle, since water is a product of the reaction 
its removal decreases the concentration of product and will drive the equilibrium reaction towards 
product formation (Brown 2014). 
The Hypothesis 
 Vaccinations are incredibly important.  There is a sub-class of vaccinations that are made 
from peptides that offers incredible advantages.  Unfortunately, a reliable way to produce peptide 
vaccinations does not exist.  The Shaw Research Group recently discovered a method to conduct 
amide bonds using SOMS nano-reactors.  We believe SOMS can be used to produce peptides – 
sequential coupling of amino acids through amide bonds.  Thus, potentially offering a method to 
reliably produce peptide vaccinations.   
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Chapter 3: The Reaction – Experimental Design 
 In order to explore the synthesis of peptides in SOMS, amino acid reactants were chosen 
such that an amino acid with a reactive amino terminus (N-terminus) will react with an amino acid 
containing a reactive carboxyl terminus (C-terminus). This project focuses on addition of amino 
acids in an N-terminus to C-terminus orientation to form the desired dipeptides. The reactive N-
terminal amino acid was chosen from a group of amino acids that would not evaporate during the 
deprotonation reaction.  Aromatic side-chain amino acids – tryptophan, phenylalanine, and 
tyrosine were chosen.  Furthermore, to control reactivity, the N-terminus end of the C-terminal 
reactive amino acids were purchased with a tert-butyoxycarbonyl (BOC) on the N-terminus amino 
group to protect it from reacting and ensuring that the carboxyl group was free to react. The C-
terminus end of the N-terminal reactive amino acids were purchased with methyl ester on the C-
terminus carbonyl group to protect it from reacting and ensuring that the amino group was free to 
react.     
Methods – Priming 
 To avoid evaporation, tryptophan was chosen as the N-terminus reactive amino acid.  When 
purchased, the N-terminus reactive amino acids, were purchased as N-terminus hydrochlorides 
that needed to undergo priming prior to coupling. To deprotonate, tryptophan methyl ester 
hydrochloride (Trp-OMe∙HCl) was dissolved in 1 M sodium hydroxide (NaOH). NaOH was the 
chosen base because when it obtains a proton it produces water and charged sodium and chloride 
ions (NaCl). The dissolved Trp-OMe ∙ HCl was added to a separatory funnel and washed with 
dichloromethane (DCM). The deprotonated tryptophan, no longer soluble in water was extracted 
with an organic solvent, DCM. This formed two distinct layers in the separatory funnel. The top 
layer contained the aqueous layer with water soluble salt (NaCl) and the bottom layer contained 
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the DCM and the deprotonated Trp-OMe. Washing with DCM was repeated two more times. The 
combined bottom layer was dried with sodium sulfate, ensuring that no water was present in the 
solution. 
Methods – Rotary Evaporator 
 To selectively separate the DCM from deprotonated Trp-OMe, the solution was placed on 
a rotary evaporator to evaporate DCM. The rotary evaporator lowers the pressure in the round 
bottom flask which lowers the boiling point of a liquid. This allows for removal of the organic 
solvent without excessively heating the sample which could be harmful to the deprotonated Trp-
OMe. The rotary evaporator also allows for minimal co-evaporation that can occur in other 
methods. 
Methods – Coupling 
 The N-terminus reactive, deprotonated, Trp-OMe was combined with the C-terminus 
reactive, amino protected tryptophan (BOC-Trp), SOMS, and a small amount of DCM. This 
process was very important in the experimental design because the organic solvent dissolved both 
Trp-OMe and BOC-Trp and the solvent which allowed for the molecules to easily enter SOMS. 
SOMS swelled to accommodate the presence of molecules in the reaction cavity (step I, Figure 
3.1) and once encapsulated inside SOMS, the molecules were much closer together.  To bring the 
molecules even closer together, the reaction vessel was placed back on the rotary evaporator to 
remove DCM (step II, Figure 3.1). Removal of DCM allowed SOMS to shrink, driving the 
reactant amino acids closer together which increased the potential for collisions for product 
formation (steps III – IV, Figure 3.1). The shrinking or closing of the SOMS can be referred to as 
a flex. The wetting and rotary evaporation step was repeated three times to ensure that all reactant 
molecules entered SOMS and were converted into the desired dipeptide product. Figure 3.1 
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demonstrates the general mechanism of a SOMS reaction where reactants and solvent enter the 
central cavity of the nano-reactor, solvent is then removed to shrink SOMS (Shaw 2017). Multiple 
additions and extractions of solvent can occur in SOMS leading to the final product. 
 
 
  
 
 
 
 
 
 
 
More important than the reaction procedure, is the ability of SOMS to repel water (Shaw 2017). 
The formation of a peptide bond is a condensation reaction which forms a molecule of water along 
with the desired dipeptide product.  In this equilibrium reaction, the water molecule can hydrolyze 
a peptide bond converting the products back into their respective starting reactants. SOMS is 
hydrophobic and water molecules produced in the reaction are driven out of the reaction cavity 
(Shaw 2017). The removal of water prevents newly formed peptide bonds from being hydrolyzed 
and removal of product drives the equilibrium reaction towards more product formation. 
 
 
 
 
 
 
Figure 3.1. Diagram of a general SOMS reaction.   
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Methods – Recovery of Product 
 After the coupling reaction the dipeptide was extracted from SOMS using DCM and 
vacuum filtration. To remove the dipeptide from SOMS, SOMS was flooded with copious amounts 
of DCM which flushed the dipeptide out of SOMS. Vacuum filtration separated the solid SOMS 
from the dipeptide dissolved in DCM. Flooding was repeated multiple times to ensure that all 
dipeptide product was flushed from SOMS. To recover the dipeptide from DCM, the resulting 
solution was placed on the rotary evaporator to remove DCM. 
Methods – 1H-NMR 
 To demonstrate dipeptide formation, 1H-NMR was utilized. The recovered dipeptide was 
suspended in deuterated chloroform (CDCl3).  The 1H-NMR was collected on a 400 MHz Bruker 
nuclear magnetic resonance instrument. All 1H NMR spectra contained organic contaminants 
which were accounted for during analysis. 
Methods – Materials 
Table 3.1. List of Chemicals and Compounds Used.   
Name Abbreviation CAS # Vendor 
Sodium Hydroxide NaOH 1310-73-2 FisherBiotech 
Dichloromethane DCM 75-09-2 Alfa Aesar 
Sodium Sulfate  Na2SO4 7757-82-6 Alfa Aesar 
Swellable Organically 
Modified Silica 
SOMS 532987-74-9 ABS Materials 
Tryptophan methyl ester 
HCl 
Trp-OMe ∙ HCl 7524-52-9 Acros Organics 
BOC-Phenylalanine BOC-Phe 13734-34-4 Chem-Impex INT’L 
INC. 
BOC-Isoleucine BOC-Ile 13139-16-7 Alfa Aesar 
BOC-Alanine BOC-Ala 15761-38-3 Acros Organics 
BOC-Valine BOC-Val 137334-41-3 Alfa Aesar 
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Methods – Experimental Procedures 
Synthesis of Deprotonated Tryptophan  
 
NH3
+
O
O
CH3
NH
NH2
O
O
CH3
NH
NaOH
DCM
H Cl
 
Scheme 3.1. Synthesis of deprotonated tryptophan. 
 
To a 250-mL beaker Trp-OMe ∙ HCl (0.450 g) was dissolved in 1M NaOH (100 mL). The 
solution was transferred to a 500-mL separatory funnel and was washed with DCM (100 mL) 3 
times. Each wash of DCM resulted in two distinct layers in the separatory funnel and the bottom 
layer was drained off. The combined bottom layers were dried with Na2SO4 and was decanted into 
a 100-mL round bottom flask (RBF). RBF was placed on the rotary evaporator to remove DCM 
(40℃ bath; 488 mbar) affording a clear oil: 1H NMR (400 MHz, CDCl3). 
General Coupling Procedure – BOC-Phe-Trp-OMe example.   
BOC-Phe (0.308 g), SOMS (2.511 g), and a small amount of DCM (1 mL) were added to 
the 100-mL RBF containing Trp-OMe (0.450 g). Followed by evaporation of the DCM (488 mbar, 
40 ˚C bath). Aliquot addition (2x) of DCM (1 mL) was added to the reaction flask and evaporated 
(488 mbar, 40 ̊ C). Dipeptide was extracted from SOMS by addition of DCM (10 mL) and vacuum 
filtration. The filtrate was placed in a 100-mL RBF and DCM (500 mbar, 40 ˚C) was evaporated 
to afford the desired product.   
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Synthesis of Phenylalanine – Tryptophan Dipeptide 
BOC-Phe-Trp-OMe was afforded as a clear oil: 1H NMR (400 MHz, CDCl3)  7.48 – 7.46 ppm, 
7.35 – 7.33 ppm, 7.24 ppm, 7.22 ppm, 7.20 ppm, 7.16 ppm, 7.09 ppm, 5.11 – 4.34 ppm, 3.68 ppm, 
3.66 ppm, 3.25 – 3.10 ppm, 2.97 – 2.90 ppm, and 1.39 ppm 
Synthesis of Isoleucine – Tryptophan Dipeptide 
BOC-Ile-Trp-OMe was afforded as a clear oil: 1H NMR (400 MHz, CDCl3)  7.46 ppm, 7.31 ppm, 
7.30 ppm, 7.06 ppm, 7.15 ppm, 5.20 – 5.21 ppm, 4.07 ppm, 3.65 ppm, 3.44 – 3.22 ppm,  
 1.78 ppm, 1.41 ppm, and 0.92 – 0.80 ppm, 
Synthesis of Alanine – Tryptophan Dipeptide 
BOC-Ala-Trp-OMe was afforded as a white solid: 1H NMR (400 MHz, CDCl3)  7.53 ppm, 7.35 
ppm, 7.18 ppm, 7.13 ppm, 7.12 ppm, 4.18 – 3.96 ppm, 3.73 ppm, 3.37 – 3.17 ppm, 1.43 ppm, 1.36 
ppm, and 1.37 ppm 
Synthesis of Valine – Tryptophan Dipeptide 
BOC-Val-Trp-OMe was afforded as a clear semi-solid: 1H NMR (400 MHz, CDCl3)  7.37 
ppm,7.20 ppm, 7.19 ppm, 7.06 ppm, 7.00 ppm, 5.39 – 4.95 ppm, 4.06 ppm, 3.67 ppm, 3.36 – 3.15 
ppm, 2.07 ppm, and 0.90 – 0.73 ppm 
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Chapter 4: The Reaction – Proof of Principle and Scope 
Proof of Principle – Synthesis of BOC -Phenylalanine- Tryptophan-OMe (BOC-Phe-Trp-OMe) 
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Scheme 4.1. Synthesis of BOC-Phe-Trp-OMe. 
The synthesis of BOC-Phe-Trp-OMe was attempted in SOMS, Scheme 4.1.  1H-NMR of 
the product mixture was obtained and compared to the respective starting materials BOC-Phe and 
the deprotonated Trp-OMe, Figure 4.1, Table 4.1.   
 
Figure 4.1.  1H-NMR stacked spectra of BOC-Phe (top), deprotonated Trp-OMe 
(middle), and BOC-Phe-Trp-OMe (bottom).    
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The 1H-NMR spectrum of Boc-Phe featured a total of eight distinct peaks (Figure 4.1).  
The backbone methine peak (peak B) is located at 3.12 - 3.05 ppm.  The sidechain peaks (peaks 
C) are located at 3.12 – 3.05 ppm for the methane peaks and 7.18, 7.20, 7.27, 7.29, and 7.31 ppm 
for the aromatic peaks. The BOC protecting group peak is located at 1.42 ppm (peak A).  The 1H-
NMR spectrum of the deprotected Trp-OMe was previously discussed.  
Table 4.1.  Summary of diagnostic BOC-Phe, Trp-OMe, and BOC-Phe-Trp-OMe 1H-NMR data 
 BOC-Phe Deprotonated Trp-
OMe 
BOC-Phe-Trp-OMe 
 Peak 
Assignment 
Position 
(ppm) 
Peak 
Assignment 
Position 
(ppm) 
Peak 
Assignment 
Position 
(ppm) 
Protecting 
Groups 
A 1.42 - - A” 1.39 
- - A’ 3.71 A” 3.68 
Backbone 
B 4.97-4.63 - - B” 5.11-4.34 
- - B’ 3.83 B” 3.66 
Side 
Chain 
C 3.12-3.05 - - C” 2.97-2.90 
C 7.18 - - C” 7.20 
C 7.20 - - C” 7.22 
C 7.27 - - C” 7.20 
C 7.29 - - C” 7.22 
C 7.31 - - C” 7.24 
- - C’ 3.30-3.05 C” 3.25-3.10 
- - C’ 7.30-7.28 C” 7.35-7.33 
- - C’ 7.61-7.61 C” 7.48-7.46 
- - C’ 7.18 C” 7.16 
- - C’ 7.12 C” 7.09 
- - C’ 6.98 C” 7.16 
 
BOC-Phe Deprotonated Trp-OMe BOC-Phe-Trp-OMe 
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The 1H-NMR spectrum of the product mixture from the synthesis of BOC-Phe-Trp-OMe 
featured sixteen peaks.  Evidence of the amino acid di-peptide backbone is present as the 1H-NMR 
spectrum features peaks at 5.11 – 4.34 ppm and 3.66 ppm.  The 1H-NMR spectrum also contains 
evidence of both phenylalanine and tryptophan side chains – the 1H-NMR spectrum features peaks 
representative of the side chain of phenylalanine at 2.97 – 2.90 ppm, 7.20, 7.22 and 7.24 ppm as 
well as the side chain of tryptophan at 3.25 – 3.10 ppm, 7.35 – 7.33 ppm, 7.48 -7.46 ppm, 7.09, 
and 6.16 ppm.  Furthermore, evidence of the presence of the BOC and methoxy protecting groups 
is clear as the 1H-NMR spectrum features a peak at 1.39 ppm and 3.68 ppm, respectively. 
Furthermore, presence of the peptide bond existing between the two amino acids is clear.  A shift 
in peak position is indicative of peptide bond formation as the protons in the dipeptide are in 
different chemical environments than in their respective monomeric amino acids.  A shift in the 
back bone methine peaks from 4.97-4.63 ppm (peak B) to 5.11-4.34 ppm (peak B”) and from 3.83 
ppm (peak B’) to 3.66 ppm (peak B”) suggest peptide bond formation.  Protons that are adjacent 
to the peptide backbone also experience a shift in the 1H-NMR spectrum.  Peaks C and C’ (3.12 - 
3.05 ppm and 3.30 - 3.05ppm, respectively) are shifted from their respective starting material 1H-
NMR – these peaks appear at 2.97 - 2.90 ppm and 3.25 - 3.10 ppm).  The remainder of the peaks 
do not experience significant changes to their chemical environment and appear in near identical 
places in both dipeptide and monomer 1H-NMR spectra.   
The presence and position of the peaks in the 1H-NMR spectrum of BOC-Phe-Trp-OMe 
suggest successful dipeptide formation. 
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Expanding the Scope – Synthesis of BOC-Ile-Trp-OMe 
NH2
O
O
CH3
NH +
O
O
CH3
CH3
CH3
NH
O
OH
CH3
CH3
CH3
CH3
NH
O
NH
O
O
CH3
NH
O
O
CH3
CH3
CH3
 
Scheme 4.2. Synthesis of BOC-Ile-Trp-OMe. 
The synthesis of BOC-Ile-Trp-OMe was attempted in SOMS, Scheme 4.2.  1H-NMR of 
the product mixture was obtained and compared to the respective starting materials BOC-Ile and 
the deprotonated Trp-OMe, Figure 4.2, Table 4.2.   
 
 
 
Figure 4.2.  1H-NMR stacked spectra of BOC-Ile (top), deprotonated Trp-OMe (middle), and 
BOC-Phe-Ile-OMe (bottom).    
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The 1H-NMR spectrum of Boc-Ile featured a total of four distinct peaks (Figure 4.2).  The 
backbone methine peak (peak B) is located at 5.01 – 4.27 ppm.  The sidechain peaks (peaks C) are 
located at 1.88 and 1.02 – 0.90 ppm for the methane peaks. The BOC protecting group peak is 
located at 1.42 ppm (peak A).  The 1H-NMR spectrum of the deprotected Trp-OMe was previously 
discussed.  
Table 4.2.  Summary of diagnostic BOC-Ile, Trp-OMe, and BOC-Ile-Trp-OMe 1H-NMR data 
 BOC-Ile Deprotonated Trp-OMe BOC-Ile-Trp-OMe 
 Peak 
Assignment 
Position 
(ppm) 
Peak 
Assignment 
Position 
(ppm) 
Peak 
Assignment 
Position 
(ppm) 
Protecting 
Groups 
A 1.42 - - A” 1.41 
- - A’ 3.71 A” 3.65 
Backbone 
B 5.01–4.27 - - B” 5.50-5.21? 
- - B’ 3.83 B” 4.07 
Side 
Chain 
C 1.88 - - C” 1.78 
C 1.02–0.90 - - C” 0.92-0.80 
- - C’ 3.30-3.05 C” 3.44-3.22 
- - C’ 7.60 C” 7.46 
- - C’ 7.30 C” 7.30 
- - C’ 7.18 C” 7.31 
- - C’ 7.12 C” 7.06 
- - C’ 6.98 C” 7.15 
 
BOC-Ile Deprotonated Trp-OMe BOC-Ile-Trp-OMe 
  
 
 
The 1H-NMR spectrum of the product mixture from the synthesis of BOC-Ile-Trp-OMe 
featured twelve peaks.  Evidence of the amino acid di-peptide backbone is present as the 1H-NMR 
spectrum features peaks at 5.50 – 5.21 ppm and 4.07 ppm. The isoleucine part of the back bone is 
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slightly over shadowed by the DCM solvent peak. The peaks presence is apparent however the 
range is not as precise. The 1H-NMR spectrum also contains evidence of both isoleucine and 
tryptophan side chains – the 1H-NMR spectrum features peaks representative of the side chain of 
isoleucine at 1.88 ppm and 1.02 – 0.90 ppm as well as the side chain of tryptophan at 3.44 – 3.22 
ppm, 7.46 ppm, 7.30 ppm, 7.31 ppm, 7.06 ppm, and 7.15 ppm.  Furthermore, evidence of the 
presence of the BOC and methoxy protecting groups is clear as the 1H-NMR spectrum features a 
peak at 1.41 ppm and 3.65 ppm, respectively. 
Furthermore, presence of the peptide bond existing between the two amino acids is clear.  
A shift in peak position is indicative of peptide bond formation as the protons in the dipeptide are 
in different chemical environments than in their respective monomeric amino acids.  A shift in the 
back bone methine peaks from 5.01 – 4.27 ppm (peak B) to roughly 5.50 - 5.21 ppm (peak B”) 
and from 3.83 ppm (peak B’) to 4.07 ppm (peak B”) suggest peptide bond formation.  Protons that 
are adjacent to the peptide backbone on the tryptophan amino acid also experience a shift in the 
1H-NMR spectrum. Peaks C’ 3.30 - 3.05 ppm are shifted from their respective starting material 
1H-NMR – these peaks appear at 3.44 – 3.22 ppm. The remainder of the peaks do not experience 
significant changes to their chemical environment and appear in near identical places in both 
dipeptide and monomer 1H-NMR spectra.   
The presence and position of the peaks in the 1H-NMR spectrum of BOC-Ile-Trp-OMe 
suggest successful dipeptide formation. 
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Expanding the Scope – Synthesis of BOC-Ala-Trp-OMe 
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Scheme 4.3. Synthesis of BOC-Ala-Trp-OMe. 
The synthesis of BOC-Ala-Trp-OMe was attempted in SOMS, Scheme 4.3.  1H-NMR of 
the product mixture was obtained and compared to the respective starting materials BOC-Ala and 
the deprotonated Trp-OMe, Figure 4.3, Table 4.3.   
 
Figure 4.3.  1H-NMR stacked spectra of BOC-Ala (top), deprotonated Trp-OMe (middle), and 
BOC-Phe-Ala-OMe (bottom).    
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The 1H-NMR spectrum of Boc-Ala featured a total of eight distinct peaks (Figure 4.3).  
The backbone methine peak (peak B) is located at 4.30 - 3.18 ppm.  The sidechain peaks (peaks 
C) are located at 1.43 ppm for the methane peaks. The BOC protecting group peak is located at 
1.45 ppm (peak A).  The 1H-NMR spectrum of the deprotected Trp-OMe was previously discussed.   
Table 4.3.  Summary of diagnostic BOC-Ala, Trp-OMe, and BOC-Ala-Trp-OMe 1H-NMR data 
 BOC-Ala Deprotonated Trp-OMe BOC-Ala-Trp-OMe 
 Peak 
Assignment 
Position 
(ppm) 
Peak 
Assignment 
Position 
(ppm) 
Peak 
Assignment 
Position 
(ppm) 
Protecting 
Groups 
A 1.45 - - A” 1.43 
- - A’ 3.71 A” 1.36 
Backbone 
B 4.30-4.18 - - B” 4.18-3.96 
- - B’ 3.83 B” 3.73? 
Side 
Chain 
C 1.43 - - C” 1.37 
- - C’ 3.30-3.05 C” 3.37-3.17 
- - C’ 7.60 C” 7.53 
- - C’ 7.30 C” 7.35 
- - C’ 7.18 C” 7.18 
- - C’ 7.12 C” 7.12 
- - C’ 6.98 C” 7.13 
 
BOC-Ala Deprotonated Trp-OMe BOC-Ala-Trp-OMe 
  
 
 
The 1H-NMR spectrum of the product mixture from the synthesis of BOC-Ala-Trp-OMe 
featured eleven peaks.  Evidence of the amino acid di-peptide backbone is present as the 1H-NMR 
spectrum features peaks at 4.18 – 3.96 ppm and 3.73 ppm. The peak for the tryptophan carbon 
back bone is overshadowed by the alanine side chain peak.  The 1H-NMR spectrum also contains 
evidence of both alaine and tryptophan side chains – the 1H-NMR spectrum features peaks 
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representative of the side chain of phenylalanine at 1.43 ppm as well as the side chain of tryptophan 
at 3.37 - 3.17 ppm, 7.53 ppm, 7.35 ppm, 7.18, 7.12 and 7.13 ppm.  Furthermore, evidence of the 
presence of the BOC and methoxy protecting groups is clear as the 1H-NMR spectrum features a 
peak at 1.43 ppm and 1.36 ppm, respectively. 
Furthermore, presence of the peptide bond existing between the two amino acids is clear.  
A shift in peak position is indicative of peptide bond formation as the protons in the dipeptide are 
in different chemical environments than in their respective monomeric amino acids.  A shift in the 
back bone methine peaks from 4.30 - 4.18 ppm (peak B) to 4.18 - 3.96 ppm (peak B”) and from 
3.83 ppm (peak B’) to 3.73 ppm (peak B”) suggest peptide bond formation.  Protons that are 
adjacent to the peptide backbone also experience a shift in the 1H-NMR spectrum.  Peaks C” at 
3.37 - 3.17 ppm is shifted from their respective starting material 1H-NMR – these C’ peaks appear 
at 3.30 - 3.05 ppm.  Peaks C” (7.53 ppm, 7.35 ppm, 7.18 ppm, 7.12 ppm, and 7.13 ppm) are shifted 
from their respective starting material 1H-NMR – these peaks appear at 7.60 ppm, 7.30 ppm, 7.18 
ppm, 7.12 ppm, and 6.98 ppm respectively.   
The presence and position of the peaks in the 1H-NMR spectrum of BOC-Phe-Trp-OMe 
suggest successful dipeptide formation. 
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Expanding the Scope – Synthesis of BOC-Val-Trp-OMe 
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Scheme 4.4. Synthesis of BOC-Val-Trp-OMe. 
The synthesis of BOC-Val-Trp-OMe was attempted in SOMS, Scheme 4.4.  1H-NMR of 
the product mixture was obtained and compared to the respective starting materials BOC-Ala and 
the deprotonated Trp-OMe, Figure 4.4, Table 4.4.   
 
Figure 4.4.  1H-NMR stacked spectra of BOC-Val (top), deprotonated Trp-OMe (middle), and 
BOC-Val-Trp-OMe (bottom).    
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The 1H-NMR spectrum of Boc-Val featured a total of four distinct peaks (Figure 4.4).  The 
backbone methine peak (peak B) is located at 5.02 – 4.26 ppm.  The sidechain peaks (peaks C) are 
located at 2.20 ppm and 1.03 – 0.88 for the methane peaks. The BOC protecting group peak is 
located at 1.44 ppm (peak A).  The 1H-NMR spectrum of the deprotected Trp-OMe was previously 
discussed.  
Table 4.4.  Summary of diagnostic BOC-Val, Trp-OMe, and BOC-Val-Trp-OMe 1H-NMR data 
 BOC-Val Deprotonated Trp-OMe BOC-Val-Trp-OMe 
 Peak 
Assignment 
Position 
(ppm) 
Peak 
Assignment 
Position 
(ppm) 
Peak 
Assignment 
Position 
(ppm) 
Protecting 
Groups 
A 1.44 - - A” ? 
- - A’ 3.71 A” 3.67 
Backbone 
B 5.02-4.26 - - B” 5.39-4.95 
- - B’ 3.83 B” 4.06 
Side 
Chain 
C 2.20 - - C” 2.07 
C 1.03 – 0.88 - - C” 0.90-0.73 
- - C’ 3.30-3.05 C” 3.36-3.15 
- - C’ 7.60 C” 7.37 
- - C’ 7.30 C” 7.19 
- - C’ 7.18 C” 7.06 
- - C’ 7.12 C” 7.00 
- - C’ 6.98 C” 7.20 
 
BOC-Val Deprotonated Trp-OMe BOC-Val-Trp-OMe 
  
 
 
The 1H-NMR spectrum of the product mixture from the synthesis of BOC-Val-Trp-OMe 
featured eleven peaks.  Evidence of the amino acid di-peptide backbone is present as the 1H-NMR 
spectrum features peaks at 5.39 – 4.95 ppm and 4.06 ppm.  The 1H-NMR spectrum also contains 
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evidence of both valine and tryptophan side chains – the 1H-NMR spectrum features peaks 
representative of the side chain of valine at 2.07 ppm and 0.90 – 0.73 ppm as well as the side chain 
of tryptophan at 3.36 - 3.15 ppm, 7.37 ppm, 7.19 ppm, 7.06 ppm, 7.00 ppm and 7.20 ppm.  
Furthermore, evidence of the presence of the methoxy protecting group is clear as the 1H-NMR 
spectrum features a peak at 3.67 ppm. The BOC protecting group is not apparent on the dipeptide 
1H NMR spectra. All of the other peaks suggest di-peptide formation so it possible that the BOC 
was cleaved in peptide bond formation. 
Furthermore, presence of the peptide bond existing between the two amino acids is clear.  
A shift in peak position is indicative of peptide bond formation as the protons in the dipeptide are 
in different chemical environments than in their respective monomeric amino acids.  A shift in the 
back bone methine peaks from 5.02 - 4.26 ppm (peak B) to 5.39 - 4.95 ppm (peak B”) and from 
3.83 ppm (peak B’) to 4.06 ppm (peak B”) suggest peptide bond formation.  Protons that are 
adjacent to the peptide backbone for the tryptophan amino acid also experience a shift in the 1H-
NMR spectrum. Peaks C” 3.36 – 3.15 is shifted from their respective starting material 1H-NMR – 
these peaks appear at 3.30 – 3.05 ppm. The remainder of the peaks do not experience significant 
changes to their chemical environment and appear in near identical places in both dipeptide and 
monomer 1H-NMR spectra.   
The presence and position of the peaks in the 1H-NMR spectrum of BOC-Val-Trp-OMe 
suggest successful dipeptide formation. 
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Chapter 5: Future Work and Applications 
Peptide Bonds and Merrifield Synthesis 
Peptide bonds form between the carboxyl end (C-terminus) of an amino acid and the 
amino end (N-terminus) of the next amino acid (Brown 2014). Peptide bond formation is a 
condensation reaction that releases water. A water molecule can also hydrolyze a peptide bond. 
This type of bond does not form in solution. The leading synthetic method of peptide synthesis is 
Merrifield synthesis (McMurry 2012). Updated papers document the procedure yields as 65 – 
92% (Boojamra 2004). for each step. Merrifield synthesis has been optimized since its 
conception however there is still room for improvement (Boojamra 2004). Through the proposed 
method several steps can be eliminated effectively decreasing the amount of time that it takes to 
run both a single step and the entire reaction. Decreasing the number of steps can also increase 
production because less starting material is lost overall (Shaw 2017). 
The proposed method is unique and is theorized to run at 100% yield. If complete closing 
is achieved, the nature of SOMS should allow for complete reactant conversion into product 
(Shaw 2017). Furthermore, if all reactant material is driven into the reaction cavity of SOMS 
then 100% product formation should be achieved (Shaw 2017). Current 1H NMR evidence 
shows lack of starting material in the spectrum suggesting that the reaction ran to completion. 
Other research projects in the research group appear to have similar results. More experiments 
are needed to statistically prove 100% yield. A quantification study will be performed in the 
future to show exact product yields. This aspect could be applied to Merrifield synthesis. If only 
dipeptides were able to be synthesized in SOMS, they could still be introduced into Merrifield 
synthesis procedure rather than single amino acids. This could cut the number of steps and 
significantly increase yield.  
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One of the major drawbacks to Merrifield synthesis is that it cannot produce a high 
enough quantity of peptide/proteins to be used in therapeutics (Boojamra 2004; Merrifield 1985). 
This is something that the proposed procedure wishes to address. The focus of the thesis has 
been on dipeptide formation and at this stage even dipeptide formation in 100% yield could 
greatly improve the efficiency of Merrifield synthesis. If dipeptides were added as “monomers” 
in Merrifield Synthesis rather than single amino acids, then proteins of greater length in higher 
yields could be synthesized. With future work on the dipeptide library and in trimer formation 
this project could improve Merrifield synthesis or form a completely independent process that 
could change peptide and protein roles in therapeutics. 
Future Work 
 Next steps in the research project would include expanding the dipeptide library to 
including all types of amino acids coupled with the initial deprotonated Tryptophan. Amino acids 
with charged side chains would be attempted to be coupled with an unprotected side chain and 
with a protected side chain. Once the library has been established further work into tripeptide 
formation would proceed. This work would focus on cleaving a protection group off the c-
terminus and adding a deprotonated amino acid in SOMS. A more thorough study of protection 
cleavage would be needed to ensure that the peptide bond is not cleaved in the process. This 
procedure could be modified from the de-protection cleavage observed in Merrifield synthesis – 
where the protection group is removed without breaking the peptide bond (Merrifield).  
 Long term goals for the proposed method would include experimentally determining the 
upper limit for protein length synthesize inside of SOMS. Correct folding of proteins would 
potentially utilize chaperon proteins in solution and could be confirmed by x-ray crystallography.  
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Applications: Cancer and Vaccines 
 The war on cancer started in the 1970’s and there have been may advances in treatment. 
However, cancer is still a prevalent disease and a leading cause of death (Weinberg 2013). Some 
types of cancers are caused by viruses. These viruses tend to use reverse transcription for 
replication and thus insert their genome into host cells and use host cell machinery for the 
replication process (Weinberg 2013). Several vaccines, like Cervarix® for HPV and the multi-
epitope melanoma peptide vaccine, have peptides in them (Senger et. al 2009). A purely 
synthetic procedure for producing peptides destined for vaccines would potentially reduce the 
need for extensive purification and growth of organisms to produce these proteins. This would 
allow for a purer sample of peptide/protein for the vaccine potentially reducing side effects to 
impurities in the vaccine.  
This method could also reduce costs in several areas. SOMS reactions are fast and are to run 
reactions at high yields (Shaw 2017). This cuts down on production time saving costs in energy, 
staffing the lab, and in reactant material. SOMS reactions do not need to run at very high 
temperatures or pressure again saving in energy costs (Shaw 2017). After a reaction, SOMS can 
be cleaned and reused for later experiments cutting costs for reaction materials.  
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